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Abstract 
Cellular circadian clocks represent a coordinated system of gene expression stimulated by both environmental and 
physiological cues that induces and maintains the rhythmicity of many metabolic processes. Circadian clocks confer the 
important benefit of anticipation of rhythmic environmental variation which serves to improve the health and survival 
of the organism. When disruption of these circadian patterns of gene expression occurs due to alterations in the physical 
(light/dark) and behavioral (feeding/sleeping) environments and/or due to genetic variation in the DNA sequence of 
clock component and clock regulated genes, negative health consequences can arise. One such consequence appears to 
be increased risk for cancer development. Circadian disruption has been associated with higher rates of tumorigenesis, 
faster tumor growth, and increased cancer severity in humans and animal models. Tumor formation is also associated 
with circadian disruption within the affected cells, and metabolic processes of the cancer host tend to lose their 
rhythmicity as the cancer becomes more severe. In addition, response to cancer treatment has been shown to have a 
time-dependent component in certain individuals. Knowledge of the type of circadian disruptions that induce or result 
from cancer can allow for temporally augmented treatments of cancer, ultimately making cancer treatments more 
effective and less harmful. 
 
Introduction 
Circadian rhythms refer to daily organismal 
fluctuations that occur consistently within a 24-hour 
cycle and correspond with anticipated changes in the 
environment. These rhythms, which include sleeping 
patterns, oscillation of gene expression, and varied 
secretion of hormones, are present in nearly all 
organisms (Bell-Pedersen et al., 2005; Kondratov et al., 
2007). They have likely evolved because of their 
ability to confer the benefit of anticipation. When a 
specific type of stimulus is encountered repeatedly and 
consistently, organismal activity can begin to predict 
the stimulus and prepare for it, aiding in survival (Bell-
Pedersen et al., 2005; Ko and Takahashi, 2006). These 
rhythms continue to approximate 24 hour cycles even 
in the absence of timed environmental stimuli 
(Kondratov et al., 2007). 
A circadian clock is a transcriptional timing 
mechanism that is present ubiquitously in mammalian 
cells such  
that isolated cells can maintain oscillatory activity and 
function (Kondratov et al., 2007). This mechanism is 
governed by multiple highly conserved positive and 
negative feedback loops whose cycles approximate 24 
hours (see figure 1). In the positive component of the 
feedback loop, BMAL1 forms a heterodimer with 
CLOCK, which then binds to E-box elements in 
promoter regions to drive the transcription of both 
bmal1 and clock genes (Bell-Pedersen et al., 2005; Ko 
and Takahashi, 2006; Kondratov et al., 2007; Stow and 
Gumz, 2011). In addition, the BMAL1/CLOCK dimer 
drives transcription of the period (per) and 
cryptochrome (cry) gene families, retinoic acid orphan 
receptor alpha (rorα), and nuclear receptor subfamily 1 
group D (nr1d2 or rev-erbα) (Ko and Takahashi, 2006; 
Kondratov et al., 2007; Stow and Gumz, 2011). PER 
and CRY proteins then create the negative feedback 
loop by forming a complex which acts to inhibit the 
transcription mediated by the BMAL1/CLOCK dimer, 
ultimately resulting in downregulation of their own  
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production (Kondratov et al., 2007; Stow and Gumz, 
2011). RORA and REV-ERBα interact with ROR 
elements to enhance and inhibit bmal1 expression, 
respectively (Kondratov et al., 2007; Stow and Gumz, 
2011). In addition, the timeless (tim) gene has been 
speculated to play a role in the maintenance of 
circadian rhythms as well, although its function may be 
more important in altering rhythms based on external 
stimuli (Kondratov et al., 2007; Engelen et al., 2013). 
The interplay of these feedback loops ultimately leads 
to consistent, daily cycles of gene/protein expression 
that can be maintained within each cell (Ko and 
Takahashi, 2006; Kondratov et al., 2007; Stow and 
Gumz, 2011). 
Nearly all cells have a clock mechanism, but the 
suprachiasmatic nucleus (SCN) or "master clock" acts 
to set the central clock in the brain by aligning its 
rhythms with light signals registered by the retina and 
transmitted through the retinohypothalamic tract (Bell-
Pedersen et al., 2005; Ko and Takahashi, 2006; 
Kondratov et al., 2007). While the SCN contributes to 
the synchronization of cellular circadian mechanisms 
in the peripheral tissues of the body, neurohumoral 
signals driven in large part by food intake are thought 
to be the primary entrainers of peripheral clocks (Bell-
Pedersen et al., 2005; Kondratov et al., 2007). 
Although multiple stimuli and activities can entrain the 
circadian system in lieu of light, light is commonly 
used to experimentally induce circadian disruption 
(Bell-Pedersen et al., 2005; Kondratov et al., 2007). 
Cellular mechanisms linking 
circadian rhythms to cancer 
Multiple studies have provided compelling evidence 
that both central and peripheral circadian clocks 
regulate many energy homeostatic functions, including 
insulin sensitivity, endocrine regulation, satiety 
signaling, cellular proliferation, and cellular substrate 
metabolism. Thus, disruption of the circadian clock 
(e.g., via dyssynchrony between light/dark cycles and 
sleep/wake/feeding behavior) has the potential to 
induce a host of disease states, including cancer. To 
examine whether circadian disruption can induce or 
exacerbate the  
development of cancer at the cellular level, several 
studies have examined and/or manipulated the 
expression of core circadian and related genes in 
human cell models of cancer. Clock, Bmal1, Cry1, and  
Per family gene expression have all been shown to be 
upregulated when host cells are exposed to radiation, 
and PER family proteins appear to play a role in DNA 
damage control and tumor suppression (Fu et al., 2002; 
Gery et al., 2006; Rana and Mahmood, 2010).  
Transfection of a Per1 overexpression vector into 
cultured human colon cancer cells exposed to ionizing 
radiation led to greater DNA damage-induced 
apoptosis than cells transfected with an empty vector 
(Gery et al., 2006). In contrast, small interfering RNA 
(siRNA) inhibition of endogenous Per1 expression led 
to less DNA damage-induced apoptosis, creating 
conditions which could readily allow for the replication 
of damaged cells and tumor formation, and revealing 
that even endogenous levels of PER1 have an 
oncostatic effect (Gery et al., 2006). Similar in vitro 
effects were seen when a Per2 expression plasmid was 
transfected into human leukemia cells, with increased 
PER2 causing an increase in cell growth arrest, 
apoptosis, and an upregulation of the tumor 
suppressing protein p53 while siRNA knockdown of 
Per2 led to a downregulation of p53 (Sun et al., 2010). 
While PER1 and PER2 have shown evidence of 
oncostatic effects, surprisingly, CRY1 may have an 
oncogenic effect. Contrary to some of the previous 
findings examining Cry gene family expression in 
cancerous tissue, Yu et al. found Cry1 mRNA 
overexpression in 8 of 10 paired tissue samples from 
patients with colorectal cancer (Yu et al., 2013).  
Additionally, they reported high CRY1 expression in 
101 of 168 paired samples, low expression in the other 
67, and a correlation between the cancer stage and 
CRY1 expression, with more severe diagnoses being 
associated with higher CRY1 expression levels (Yu et 
al., 2013). To explore the role of CRY1 in 
tumorigenesis, Cry1 was overexpressed in a human 
colorectal cancer cell line, and showed that cells 
transfected with a Cry1-expressing plasmid 
demonstrated significantly more cellular growth, 
proliferation, and increased migration capacity than 
those transfected with an inert control (Yu et al., 2013). 
In addition, siRNA knockdown of endogenous Cry1 
expression inhibited cell colony formation and reduced 
migration capacity (Yu et al., 2013). These studies 
point to a putative non-circadian function of Cry1 in 
cancer etiology. 
Bmal1 also appears to play a role in cancer risk and 
oncogenesis. 
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Figure 1. The BMAL1/CLOCK heterodimer drives the transcription of several genes. PER and CRY family proteins form 
heterodimers that inhibit the actions of the BMAL1/CLOCK heterodimer. RORA and REV-ERBα act to activate and inhibit bmal1 
transcription, respectively. Adapted from Stow and Gumz, 2011 (JASN). 
 
Bmal1 deficient human cells are less likely to undergo 
cell cycle arrest due to DNA damage, and knockdown 
caused by Bmal1 targeting small hairpin RNAs 
(shRNAs) reveal a potential modulatory effect of p53 
on p21, a process which may be involved in DNA-
damage induced apoptosis (Mullenders et al., 2009; 
Rana and Mahmood, 2010). In murine colon cancer 
cells, shRNA bmal1 knockdown produced similar 
results, including increased cell growth, decreased 
apoptosis, as well as downregulation of Per family 
genes and upregulation of rev-erbα (Zeng et al., 2010). 
The protein DBC1 (deleted in breast cancer 1), which 
is speculated to be associated with tumorigenesis, has 
been shown to regulate and increase REV-ERBα 
expression and stability as well as modulate its 
transcription repression activity on Bmal1 (Chini CC et 
al., 2013; Chini EN et al., 2013). In human embryonic 
kidney cells, the tandem transfection of Dbc1 and Rev-
erbα plasmids resulted in lower Bmal1 transcription 
and cell cycle arrest than the transfection of either 
plasmid alone or a control plasmid (Chini EN et al., 
2013). Independent of the interaction of DBC1 with 
circadian genes, overexpression of DBC1 has been 
reported in several different cancers and is correlated 
with poorer prognoses in breast carcinoma, lymphoma, 
colorectal cancer, gastric carcinoma, and others (Cha et 
al., 2009; Lee et al., 2011; Kim et al., 2012; Park et al., 
2013; Zhang et al., 2013). The downstream effects of 
DBC1 on REV-ERBα and subsequently on Bmal1 can 
lead to disruption of typical protein oscillations, which 
could be a factor in the physiological effects on tumor 
growth associated with the deletion of DBC1 (Chini 
EN et al., 2013). 
Circadian gene dysregulation in 
cancerous tissue 
The relationship between circadian rhythms and cancer 
is also seen at the cellular level when comparing 
cancerous to non-cancerous human tissue. Both 
circadian rhythmicity and core circadian gene 
expression appear to be disrupted in cancerous cells. 
Several circadian genes have been shown to be 
correlated with poor prognosis when overexpressed in 
various cancers, including Cry1 in colorectal cancer 
and Timeless in lung cancer (Rana and Mahmood, 
2010; Yoshida et al., 2013; Yu et al., 2013). A series of 
studies using tissue from 30-70 patients with 
subcortical gliomas showed abnormal expression 
patterns of critical circadian genes in high-grade versus 
low-grade gliomas and high-grade gliomas compared 
to surrounding non-glioma tissue, in which higher 
levels of CLOCK and lower levels of PER1, PER2, 
CRY1, CRY2 and corresponding mRNA were reported 
(Xia et al., 2010; Luo et al., 2012; Chen et al., 2013). 
Tissue samples from 32 patient skin biopsies revealed 
lower mRNA levels of the same circadian genes 
excluding Cry2 that were seen in of both malignant 
melanoma and nonmalignant nevus tumors compared 
to surrounding skin tissue (Lengyel et al., 2013). 
Downregulation of PER1 was also shown in tissue 
collected from 38 patients who had been diagnosed but 
not yet treated for buccal squamous cell carcinoma;  
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this effect was significantly correlated with increased 
risk of metastasis and clinical stage, where more severe 
risk and diagnosis corresponded with more PER1 
downregulation (Zhao et al., 2013). Nevertheless, the 
studies described above have their limitations since 
they all collected their human tissue samples from a 
single three hour period and did not categorize tissue 
by collection time (Zhao et al., 2013). While these 
studies do not measure the target genes over time due 
to practical considerations of subject burden, since they 
all compare the cancerous tissue to non-cancerous 
tissue collected at the same time from the same patient, 
the compared samples do provide important 
information related to protein abundance of circadian 
components and cancer risk. 
Recently, a study by Chen et al. used 55 samples of 
breast cancer and paired non-cancerous tissue collected 
from 5 different time points from 10am until 8pm and 
reported differential expression of at least one PER 
protein for all type II or type III breast cancer tissue 
samples compared to their paired control tissue (Chen 
et al., 2005). The overall expression of the samples was 
not lower as they were in the previous studies, which 
could be due to variability in collection time points, 
although the fact that distinct cell populations of the 
same cancer tissue expressed different PER expression 
could indicate heterogeneity even within breast cancer 
cell populations (Chen et al., 2005). An abnormal 
pattern of circadian gene expression was also observed 
in tissue from 38 patients with diagnosed but not 
treated colorectal carcinoma collected across 6 time 
points between 10am and 10pm; PER2 
immunostaining showed a heterogeneous expression 
pattern in the cancerous tissue compared to the 
homogeneous expression seen in paired non-cancerous 
tissues, with a trend of decreased PER2 expression in 
cancerous versus non-cancerous tissue (Wang et al., 
2011). A study by Lin et al. examined mRNA 
expression of several circadian genes, including Per 
and Cry family genes, as well as Clock, Bmal1, and 
Timeless, and revealed significant decreases in levels 
of Per, Cry2, and Timeless expression in hepatocellular 
carcinoma samples collected from 46 patients in one of 
five time points from 8am to 6pm (Lin et al., 2008). 
Heterogeneous immunostaining patterns were also 
apparent in many of the cancerous as opposed to paired 
non-cancerous tissue samples, and the number of genes 
whose expression was disrupted was positively 
correlated with tumor size (Lin et al., 2008). These 
studies reveal that cancerous tissues show both 
disrupted and less homogenous expression of circadian 
genes than their non-cancerous counterparts, but cannot 
convey causal relationships between these factors. 
Transgenic mouse models 
As convincing as the accumulation of human and 
cellular data may be, animal models can provide even 
more insight by allowing for genetic manipulations and  
near complete control of environmental factors. 
Transgenic mouse models with functional disruptions 
of circadian genes have many phenotypes that parallel 
the pathologies seen in humans experiencing consistent 
circadian disruptions. Clock dominant negative ∆19 
mutant mice show hypoinsulinemia, hyperglycemia, 
and obesity, consistent with the high risk of diabetes 
and obesity seen in humans (Kondratov et al., 2007). 
Bmal1-/- mice show premature aging, sterility, 
metabolic defects, and shorter average lifespan than 
their wild-type counterparts (Kondratov et al., 2007). 
Interestingly, mice with only one copy of Bmal1 
(Bmal1+/-) exhibit increased spontaneous tumors as 
well as an increased sensitivity to tumor formation 
after irradiation (Lee et al., 2010). Per2-/- mice show a 
decrease in DNA damage response along with higher 
rates of tumor formation from exposure to low levels of 
ionizing radiation, which coincides with the human 
data showing a downregulation of Per expression in 
cancerous versus non-cancerous tissue (Kondratov et 
al., 2007; Rana and Mahmood, 2010). In addition, 
mPer2m/m homozygous mutant mice have higher 
mortality rates and are naturally cancer prone (Fu et al., 
2002). The mPer2m/m mice also have higher sensitivity 
to the effects of radiation, including a more than ten-
fold increase in the likelihood of cancer induction, and 
show resistance to radiation induced-apoptosis, further 
emphasizing the importance of a functional PER2 in 
tumor suppression (Fu et al., 2002). Knockout mice 
lacking both Per1 and Per2 or both Cry1 and Cry2 
were shown to have higher rates of spontaneous tumor 
formation, higher rates of tumorigenesis after 
irradiation, and increased tumor formation and growth 
when exposed to continuous, alternating phase 
advances and delays (Lee et al., 2010). However, Per1-
/-
, Cry1-/-, Cry2-/- and Rev-erbα-/- mice do not have 
strong phenotypes, with Per1-/- mice showing increased 
drug sensitivity but little else, both Cry1-/- and Cry2-/- 
mice exhibiting high bone mass but no metabolic or 
tumorigenesis abnormalities, and Rev-erbα-/- mice 
being phenotypically indistinguishable from wild-type 
mice (Kondratov et al., 2007; Rana and Mahmood, 
2010). 
Surgical and environmental 
circadian disruption in animal 
models 
Though transgenic models can shed light on gene 
function, total knockout models have limitations in that 
all tissues are lacking a specific gene, and the organism 
has undergone the entirety of its development without 
that gene. Because of these possible confounding 
factors, several studies have employed environmentally 
or surgically induced circadian disruption rather than 
genetic interventions and have demonstrated that such 
manipulations can influence morbidity and cancer 
sensitivity. Rats exposed to continuous or increased  
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daily light rather than the typical 12 hour light/dark 
cycle have shown increased spontaneous 
tumorigenesis, decreased lifespan, as well as more 
infectious diseases, abdominal obesity, hyperglycemia, 
and hyper-cholesterolemia (Vinogradova et al., 2009; 
Bukalev et al., 2012). Mice with ablated SCN regions 
showed completely disrupted rest/activity patterns, 
along with phase shifts and blunted amplitudes of 
processes that typically showcase 24-hour rhythmicity, 
such as body temperature, serum corticosterone, and 
circulating lymphocyte count (Filipski and Lévi, 2009). 
Additionally, subjection to chronic jet lag via 
alterations in light/dark timing disrupted rest/activity, 
body temperature, and serum corticosterone patterns, 
similar to SCN lesions (Filipski et al., 2004). 
Moreover, jet lag conditions caused a marked 
disruption of the typical circadian expression of all the 
examined genes, including bmal1, cry1, per2, and rev-
erbα mRNA in liver tissue, and increased the risk of 
development of several cancers (Filipski et al., 2005; 
Lee et al., 2010). 
In order to focus on the effects of these disruptive 
factors on tumor growth, xenografts of human cancer 
cells or induction of tumors by other means can be 
informative. Filipski et al. performed several 
experiments exploring various methods of circadian 
disruption and recovery, and their effects on tumor 
growth (Filipski and Levi, 2009). Destruction of the 
SCN after tumor inoculation produced accelerated 
growth in both slow-growing (pancreatic 
adenocarcinoma) and fast-growing (Glasgow 
osteosarcoma) tumors, doubling the size of the tumors 
compared to their sham lesioned counterparts by day 
12 and 22, respectively (Filipski and Levi, 2009). In 
non-lesioned mice bearing tumors, meal timing was 
used as an entrainment factor, with a four hour feeding 
time at the beginning of the light phase causing a 
decrease in tumor growth for both types of tumors as 
compared to mice given access to food ad libitum 
(Filipski and Levi, 2009). Chronic jet-lag simulated by 
five 8-hour light advances caused an increase in 
mortality rates and nearly a 50% increase in Glasgow 
osteosarcoma tumor size by day 11 compared to mice 
exposed to normal light/dark cycles (Filipski et al., 
2004; Filipski and Levi, 2009). Chronic jet lag also 
caused phase shifts and altered mRNA expression of 
bmal1 and per2 in the livers of tumor-bearing mice 
(Filipski et al., 2005). To investigate whether meal 
timing could mitigate the increased tumorigenesis 
effect cause by chronic jet lag, mice were exposed to 
the jet lag conditions but also given a consistent cycle 
of 12 hours access to food then 12 hours without 
access, which slowed tumor growth to rates to those 
similar to the non-jet lagged mice (Filipski and Levi, 
2009). Meal timing also nearly restored per2 and rev-
erbα mRNA expression patterns but dampened those of 
bmal1 in the liver, and induced a more typical 
sinusoidal expression of per2, bmal1, and rev-erbα in 
the tumor tissue (Filipski and Levi, 2009). 
Although a relationship between the disruption of 
specific circadian gene expression and disordered SCN 
function or light/dark hours has consistently been 
demonstrated, the exact nature of the relationship 
between circadian gene expression and oncogenesis is 
still unclear. To examine if the expression of a single 
circadian gene could induce the tumorigenic effects 
observed in light-induced circadian phase shifts, Yu et 
al. examined the overexpression of a specific circadian 
gene, Cry1, in a xenografted tumor (Yu et al., 2013). 
Nine mice were administered bilateral subcutaneous 
injections of human colorectal cancer cells, with one 
side being injected with cells that overexpressed Cry1 
and the other maintaining endogenous levels of Cry1 
expression (Yu et al., 2013). After four weeks, tumors 
overexpressing Cry1 were over 50% larger and heavier 
than tumors originating from wildtype Cry1 (Yu et al., 
2013). Another study subcutaneously injected murine 
colon cancer cell lines that had either normal or 
downregulated bmal1 expression into the axilla of mice 
to induce tumor growth (Zeng et al., 2010). Tumors 
derived from cell lines with downregulated bmal1 grew 
faster than those with normal bmal1 expression, with 
the bmal1 suppressed tumor growing to twice the size 
of the control tumor after 31 days (Zeng et al., 2010). 
More experiments utilizing this tumor-specific/gene-
specific abnormal expression model would be 
informative to the oncogenic and oncostatic properties 
for all circadian genes. 
Circadian disruption in humans and 
the melatonin hypothesis 
The importance of circadian rhythms in relation to 
various aspects of human health has been a topic of 
extensive research. Several studies have indicated that 
people with jobs causing "jet-lag" and disallowing 
typical sleep patterns, such as shift workers, pilots and 
flight attendants, are at a higher risk for health issues 
including heart disease, obesity, mood disorders, 
diabetes, gastrointestinal symptoms, and overall 
mortality (Healy and Waterhouse, 1995; Anisimov, 
2003; Bray and Young, 2007; Kondratov et al., 2007; 
Pan et al., 2011; Schernhammer and Thompson, 2011). 
Similar results can be found for people with profound 
sleep disturbances not necessarily caused by 
occupation (Hublin et al., 2007; Kondratov et al., 2007; 
Adamantidis and de Lecea, 2008). Intriguingly, this 
increased risk extends to several cancers, but is most 
commonly seen in hormonally regulated cancers such 
as breast, prostate, ovarian, and thyroid cancer (Davis 
et al., 2001; Hansen, 2001; Anisimov, 2003; 
Schernhammer et al., 2003; Megdal et al., 2005; 
Anisimov, 2006; Kubo et al., 2006; Schernhammer et 
al., 2006; Blask, 2009; Hansen and Stevens, 2011; 
Poole et al., 2011; Monsees et al., 2012; Luo et al., 
2013). In fact, the International Agency for Research 
on Cancer Working Group concluded that shift-work 
with circadian disruption is probably carcinogenic to 
humans (Straif et al., 2007). Mortality risk for cancer 
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patients increases when severe rest-activity pattern 
disruptions are present, and behavioral and molecular 
circadian disruptions are more frequent and prominent 
in later stages of cancer development (Mormont and 
Lévi, 1997; Mormont et al., 2000; Mormont and 
Waterhouse, 2002; Innominato et al., 2009; Innominato 
et al., 2012). 
Certain cancer rates are higher in industrialized 
countries, and light pollution is thought to be a possible 
contributor to this phenomenon (Anisimov, 2006; 
Kloog et al., 2010; Spivey, 2010). This theory, known 
as the melatonin hypothesis, attributes increased cancer 
risk to decreased melatonin excretion due to the 
presence of light at night. Melatonin levels have a 
typical circadian rhythmicity, with the peak of 
circulating melatonin levels occurring in the middle of 
the night around 4am, a time at which natural light is 
rarely present and most humans are asleep (Healy and 
Waterhouse, 1995; Rohr and Herold, 2002; Stow and 
Gumz, 2011). However, with the advent of artificial 
light, sleep/wake and work cycles have become more 
malleable, and light exposure can easily occur during 
times that are atypical evolutionarily. It is important to 
note that melatonin production in the pineal gland can 
be suppressed by both natural and artificial light 
(Stevens et al., 1992; Rohr and Herold, 2002; 
Anisimov, 2003; Nakahara et al., 2003; Blask, 2009; 
Stow and Gumz, 2011), and plasma melatonin levels 
are often used as an indicator of circadian phase 
because of the interconnectedness of the pineal gland 
and the SCN. Anomalies in melatonin cycles are 
considered symptomatic of circadian disruption (Healy 
and Waterhouse, 1995; Rohr and Herold, 2002; 
Nakahara et al., 2003). 
While suppression of melatonin occurs as a result of 
exposure to visible light, melatonin synthesis remains 
rhythmic in the absence of light. Therefore, if 
melatonin is a protective factor in tumorigenesis, then 
populations exposed to less light should have lower 
cancer risks. Indeed, Alaska, Canada, and Greenland 
had less than half the global incidence of breast cancer 
based on epidemiological data collected from 1968-
1988, where the darkness during the winter months 
may have bestowed a protective element (Erren and 
Piekarski, 1999). Unfortunately, this protective element 
may be declining, as breast cancer rates have continued 
to rise since the previous data was collected (Fredslund 
and Bonefeld-Jørgensen, 2012). While still lower than 
global incidence rates, epidemiological data from the 
range of 1988-2008 in Greenland, Canada, Arctic 
Russia, and Alaska have shown a consistent trend of 
increasing breast cancer incidence (Fredslund and 
Bonefeld-Jørgensen, 2012). Changing environmental 
factors, including increased exposure to light at night 
through TV and computer screen time and outdoor 
high intensity output lamps, may be contributing to the 
increase in breast cancer rates (Pauley, 2004). 
To substantiate the claim that levels of light at night 
exposure can lead to higher breast cancer incidence, a 
study by Kloog and colleagues used a composite image 
for nighttime light levels in 1996/1997 from the daily 
readings by U.S. satellites to assess nighttime light 
levels across 164 countries, and compared these levels 
to breast cancer rates reported by GLOBOCAN (Kloog 
et al., 2010). The investigators reported that higher 
light at night levels were associated with higher breast 
cancer incidence rates even after controlling for other 
risk factors, which corresponds with their previous 
findings in communities in Israel (Kloog et al., 2008; 
Kloog et al., 2010). In addition, intensity of light 
exposure in the bedroom during sleeping hours has 
been indicated to be a strong predictor of breast cancer 
while controlling for other known predictive factors 
(Anisimov, 2003; Blask, 2009; Kloog et al., 2011). 
Environmental studies of light exposure during night 
hours may be confounded by the variability of light 
intensities and frequencies across countries and 
settings. Investigations of blindness and visual 
impairment have been performed to control for such 
environmental variability (Rohr and Herold, 2002). 
The possibility of blindness as a protective trait has 
been examined using public data available from the last 
five decades from national cancer registries, blindness 
registries, and national hospital discharge surveys. The 
data were derived from Norway, USA, Sweden, and 
Finland, collectively including over 50000 visually 
impaired patients (Hahn, 1991; Feychting et al., 1998; 
Verkasalo et al., 1999; Kliukiene et al., 2001; Rohr and 
Herold, 2002; Pukkala et al., 2006). Consistent with the 
melatonin hypothesis, these studies have reliably 
reported that women with near to total blindness have 
approximately half the incidence of breast cancer as 
compared to sighted women (Hahn, 1991; Feychting et 
al., 1998; Verkasalo et al., 1999; Kliukiene et al., 2001; 
Rohr and Herold, 2002; Pukkala et al., 2006). 
While the above findings are consistent with the 
melatonin hypothesis, more direct evidence for the role 
of melatonin in cancer risk can be found in clinical and 
experimental data. In humans, decreasing melatonin 
levels have been suggested as markers for certain types 
of cancer, particularly those in which tumors are 
hormonally dependent (Karasek et al., 2000). In 
addition, lower melatonin levels in urine have been 
shown in women with breast cancer compared to 
matched controls, and diminished pineal gland 
function, which results in lower melatonin levels, has 
long been suggested to be involved in the promotion of 
breast cancer and other cancers (Cohen et al., 1978; 
Schernhammer and Hankinson, 2005). A study by 
Schernhammer and Hankinson examined the 
association of urinary melatonin and breast cancer risk 
by taking urinary samples from nearly 30000 cancer-
free women who participated in the Nurse's Health 
Study from 1996-1999 (Schernhammer and Hankinson, 
2005). A four-year follow-up revealed that the quarter 
with the lowest urinary melatonin had over twice as 
many cases of breast cancer than the quarter with the 
highest urinary melatonin concentration 
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(Schernhammer and Hankinson, 2005). A 
comprehensive summary of the various mechanisms by 
which melatonin may produce an oncostatic effects are 
presented by Srinivasan and colleagues (Srinivasan et 
al., 2008). 
Melatonin has been shown to have anti-oncogenic 
effects in several human cancer cell lines. The effects 
of application of physiological levels of melatonin, 
pharmacological levels of melatonin, or a control 
diluent for 24 hours was examined in human breast and 
prostate cancer cell culture; physiological levels of 
melatonin were shown to decrease cell proliferation in 
these cell lines, which may be due to their modulation 
of the cell cycle length or inhibition of DNA synthesis 
(Cos et al., 2002; Jung-Hynes et al., 2011; Kostoglou-
Athanassiou, 2013; Liu et al., 2013). In addition, 
physiological levels of melatonin were shown to 
stimulate multiple DNA repair systems and reduce the 
metastatic properties of human breast cancer cells 
(Sliwinski et al., 2007; Liu et al., 2013). At 
pharmacologically relevant levels, melatonin decreased 
cell proliferation in a variety of cancer cell type, 
including cervical cancer, gliomas, and ovarian cancer, 
and has also been shown to induce apoptosis in specific 
cancer cell lines without cytotoxicity to any non-
cancerous cells (Kostoglou-Athanassiou, 2013; 
Rodriguez et al., 2013). 
To examine the tumorigenic effects of "light at night" 
in animal models, Blask and colleagues exposed rats 
with human breast cancer xenografts to one of six 
different intensities of light during their normal dark 
phase, ranging from total darkness to bright light, and 
reported a dose-related tumor growth rate and blood-
melatonin suppression, with more light at night 
corresponding to faster tumor growth rates and lower 
blood-melatonin levels (Blask et al., 2009). One 
noteworthy finding was that "dim light" (0,08µW/cm2) 
caused less melatonin suppression but nearly 
equivalent levels of tumor growth as "bright light" 
(345µW/cm2) at night (Blask et al., 2009), further 
supporting the importance of light at night and 
melatonin levels. In another study, blood collected at 
night from pre-menopausal women was perfused into 
in situ rat hepatomas or human breast cancer 
xenografts, resulting in inhibited signal transduction 
activity; this oncostatic effect was not present when the 
tumors were perfused with blood collected during the 
daytime or at night after 90 minutes of bright light 
exposure (Blask et al., 2005). Melatonin levels were 
five times higher in the blood collected at night without 
light exposure than the other blood collection 
conditions, and the introduction of a nonselective 
melatonin receptor antagonist blocked the tumor-
suppressing effects, providing support for melatonin as 
the primary oncostatic factor in these studies (Blask et 
al., 2005). 
In rats exposed to dim light (8,8µW/cm2), near  
 
darkness (1-2,5µW/cm2), or complete darkness 
(0µW/cm2) and implanted with human breast cancer 
xenografts, latency-to-onset growth was recorded at 11 
days for dim light exposure, 12 days for near darkness, 
and 15 days for complete darkness, demonstrating an 
increase in latency with decreasing levels of light at 
night (Dauchy et al., 2011). The same effect was 
observed in rats with hepatomas, reporting latency-to-
onset at 5, 9, and 13 days with decreasing light at night 
(Dauchy et al., 2011). Blood melatonin levels in non-
tumor bearing rats exposed to the varying degrees of 
light at night intensity were similar in dim light at night 
as in daytime, and a ten-fold increase of melatonin 
levels in near darkness compared to dim light was 
observed, which increased even further to normal 
levels in complete darkness (Dauchy et al., 2011). 
These findings expose a direct relationship between 
intensity of light at night and peak nighttime melatonin 
levels and provide evidence that disruption of 
melatonin expression can exacerbate tumor growth 
(Dauchy et al., 2011). 
To examine the mediating effects of melatonin 
administration on tumor development, intestinal tumors 
were induced in rats by giving them five injections of 
1,2-dimethylhydrazine weekly for six months with or 
without a corresponding nighttime injection of 
melatonin (Anisimov et al., 1997). Of the 21 rats given 
the carcinogen alone, all developed at least one tumor 
with an average of 3,8 tumors per rat, and of the 21 
given melatonin as well as the carcinogen, only 14 
developed any tumors and had an average of 1,5 
tumors per rat (Anisimov et al., 1997). In another 
study, tumors in the vagina and uterine cervix were 
induced in mice by applying the same carcinogen 
intravaginally twice a week for 3 hours each with or 
without the five nighttime injections of melatonin per 
week (Anisimov et al., 2000). Of the 20 mice exposed 
solely to the carcinogen, 10 tumors developed in the 
vagina and uterine cervix, 8 of which were classified as 
malignant, and of the 20 rats given melatonin along 
with the carcinogen, only 5 developed tumors with 
none in the uterine cervix, and all were benign 
(Anisimov et al., 2000). To examine the joint and 
independent effects of testosterone and melatonin, rats 
were given an intragastric dose of the carcinogen 
dimethylbenzathracene to induce the appearance of 
mammary tumors; ovariectomies were performed on 
rats with tumors that developed within 12 weeks, and 
rats were treated with testosterone only, a combination 
of testosterone and melatonin, or untreated (Cos et al., 
2006). Mice treated with solely testosterone showed 
steep increases in the number and growth rate of 
tumors, and these effects were mitigated by the 
administration of melatonin, returning both values to 
similar levels as the untreated rats (Cos et al., 2006). In 
addition, the melatonin group showed the highest 
survival rates of any of the groups (Cos et al., 2006). 
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Melatonin treatment and anticancer 
effects 
Melatonin has been studied for its effectiveness in 
cancer treatments and is especially appealing because 
of its endogenous presence and lack of adverse side 
effects (Vijayalaxmi et al., 2002; Jung and Ahmad, 
2006). Several non-randomized studies lacking placebo 
controls have shown potential for the usage of 
melatonin in addition to other anticancer treatments, 
demonstrating increased measures of quality of life, 
decreased anxiety, and potential for response to 
anticancer treatment in patients who were previously 
unresponsive without melatonin (Jung and Ahmad, 
2006). A small study conducted by Lissoni and 
colleagues examined 63 patients with non-small lung 
cancer who did not respond to cisplatin treatment and 
thus had no other viable treatment options (Lissoni et 
al., 1992). The patients were randomly assigned to a 
group receiving only supportive care, which included 
steroid and anticonvulsant agents, or a daily evening 
dose of 10 mg of melatonin; patients treated with 
melatonin showed higher survival rates and 
performance status (Lissoni et al., 1992). A similar 
study headed by Lissoni supplemented 50 patients with 
unresectable brain metastases with either supportive 
care alone, or supportive care and a daily 20 mg dose 
of melatonin in the evening (Lissoni et al., 1994). The 
mean survival times were 5 months with supportive 
care alone and 9 months with melatonin added, with a 
mean progression free period of 6 months and 3 
months, respectively (Lissoni et al., 1994). In addition, 
the melatonin group suffered from fewer steroid-
induced complications and showed improved quality of 
life (Lissoni et al., 1994). Another study of 60 patients 
with non-small lung cancer showed increased survival 
when given interleukin and melatonin versus a 
chemotherapy treatment of cisplatin and etoposide 
(Barni et al., 1995). In a larger study with 250 patients 
with metastatic solid tumors from lung cancer, face or 
neck cancer, breast cancer, or gastrointestinal tract 
neoplasms, patients were treated, with a chemotherapy 
regime based on their cancer type, with or without 20 
mg of melatonin each evening (Lissoni et al., 1999). 
Patients given melatonin in the evenings had a clinical 
response rate of 34%, while only 15% of those without 
melatonin treatment achieved a clinical response, and 
the groups showed a one year survival rate of over 50% 
and less than 25%, respectively (Lissoni et al., 1999). 
In addition, the average progression-free time was 
approximately 4 months for the group receiving 
chemotherapy alone and was 9 months for the 
melatonin group, and the majority of chemotherapy-
related toxicities had less than half the frequency in the 
melatonin and chemotherapy versus the chemotherapy 
alone group (Lissoni et al., 1999). Similar levels of 
increased chemotherapy tolerance, higher survival, and 
increased response were also found in a five-year study  
of 100 patients with non-small lung cancer (Lissoni et 
al., 2003). Other studies have reported consistent 
results of increased survival, tolerance, progression-
free time, as well as reductions in anxiety and pain 
(Vijayalaxmi et al., 2002). Overall, the collection of 
data on melatonin use in tandem with current cancer 
treatment appears to be very positive, with minimal 
additional risk. 
Circadian rhythmicity of response 
to anticancer drugs 
In order to examine the effect of drug administration 
timing, animals entrained to a 12 hour light/dark cycle 
were divided into one of several groups representing 
different circadian times of drug administration. 
Differential rates of survival, tumor growth, activity, 
maximum dose, weight loss, leukocyte count, etc., 
were observed among the timed treatment groups, 
which was attributed to circadian variations in 
tolerability, efficacy, and side effects (Blumenthal et 
al., 1999). The most beneficial time points of lowest 
toxicity or highest efficacy observed in animal studies 
can then be extrapolated to chronotherapeutic 
administration of chemotherapy for human patients and 
can be optimized through computational modeling 
(Lévi et al., 2010). Chronotherapy, a method of 
chronomodulated drug administration that accounts for 
the interaction of cellular circadian rhythms and the 
corresponding changes in efficacy and tolerance of 
anti-cancer drugs, ideally allows for greater survival 
while maintaining or potentially decreasing the 
intensity and number of side effects (Librodo et al., 
2012). Currently, at least thirty anticancer drugs have 
demonstrated up to a ten-fold tolerability variance 
depending on time of day administered, most in which 
the highest tolerability time point corresponded with 
the highest anti-tumor efficacy (Lévi, 1996; Lévi et al., 
2010). The increase in drug efficacy at specific 
circadian time points continues even when the 
cancerous cells exhibit disrupted or completely ablated 
circadian organization (Lévi et al., 2010). These anti-
cancer effects in rodents help to inform cancer 
treatment strategies that can be used in humans. 
Several clinical trials have been performed in an 
attempt to highlight the potential advantages of 
chronotherapy versus conventional drug 
administration, particularly using the antimetabolite 5-
fluorouracil in the treatment of colorectal cancer. A 
phase I trial of 5-fluorouracil administered with 1-folic 
acid utilized programmable pumps to deliver five days 
of timed infusions, lasting from 10pm to 10am and 
peaking at 4am, to several groups of patients with 
metastatic colorectal cancer (Garufi et al., 1997). The 
doses were increased with each group given this 
treatment to determine the maximum tolerated dose, 
and the timed treatment revealed low toxicity and 
promisingly high efficacy rates for both previously 
treated and untreated patients (Garufi et al., 1997).  
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A phase II trial utilizing a similar drug administration 
schedule with the addition of oxaliplatin showed that 
the chronomodulated drug administration allowed for 
higher drug doses, resulted in higher rates of 
progression free and overall survival time, and caused 
fewer severe side effects (e.g., stomatitis) compared to 
patients given constant rates of infusion (Lévi et al., 
1994). Additional randomized phase II trials comparing 
chronomodulated administration and constant 
administration have shown that groups with advanced 
colorectal cancer subjected to chronomodulated drug 
infusion had up to a 20% increase in objective response 
rate, increased tolerance, severely decreased 
frequencies of dose-limiting toxicity effects, and fewer 
patients dropping out from treatment when compared 
to conventional flat-rate infusions (Buroker et al., 
1994; Lévi et al., 1994; Focan et al., 2000; Librodo et 
al., 2012). A meta-analysis performed on five studies 
comparing these two treatment plans in advanced 
colorectal cancer showed that chronomodulated drug 
administration provided a significant increase in 
overall survival rates while maintaining similar 
frequencies and intensities of side effects (Liao et al., 
2010). In addition, a study of 77 patients with 
metastatic colorectal cancer who had previously shown 
to be resistant to treatments involving 5-fluorouracil, 
oxaliplatin, and leucovorin were treated with these 
drugs in a chronomodulated schedule, and were able to 
halt disease progression for a median time of 5,5 
months in 61 of the patients (Gholam et al., 2006). 
To further investigate the potential benefits of 
chronomodulated versus conventional flat-rate 
administration, phase III trials have been conducted. A 
trial of 554 previously untreated patients with 
colorectal cancer were randomly assigned to be given 
either a conventional 2-day flat rate infusion or a 
chronomodulated 4-day infusion of fluorouracil, 
oxaliplatin, and leucovorin (Giacchetti et al., 2006). 
Sex appeared as an important factor in the efficacy of 
chronomodulated versus conventional treatment; men 
showed a median survival rate of 21 months versus 18 
months and a 2-year survival rate of 44% versus 34% 
for chronomodulated versus conventional treatment, 
respectively, while women showed a median survival 
rate of 16 months versus 19 months, and a 2-year 
survival rate of 27% versus 41% (Giacchetti et al., 
2006). While treatment-related toxicities were similar 
both between treatment groups and sexes, the overall 
trend shows that chronomodulated treatment was 
beneficial in men and was potentially detrimental in 
women (Giacchetti et al., 2006). A meta-analysis 
including two other phase III trials and totaling 842 
patients comparing the same two schedules of drug 
administration concluded that chronomodulated 
administration of anti-cancer drugs is safe and 
beneficial for males but not females, which may 
partially be a result of the majority of the relevant 
animal testing being performed on male rodents 
(Giacchetti et al., 2012). 
Because of heterogeneity among patients, the 
individualization of treatment plans has the potential to 
be very efficacious. Patients can have differing activity 
schedules, tumor growth rates, and discrepancies 
between tumor and other cell cycles which all can be 
monitored and used to determine the most effective and 
least risky treatment plan (Bernard et al., 2010). 
Mathematical simulations of individualized treatments 
based on these patient characteristics have shown 
methods to optimize tumor cell death while minimizing 
non-tumor cell death by exploiting the differing 
circadian profile of the tumor cells compared to the 
patient's other cells, and have even suggested 29 hour 
treatment intervals as a possible method to maintain 
efficacy while minimizing risk due to individual 
variations in optimal administration time (Bernard et 
al., 2010). Investigation of individualized timed 
treatment is especially important since the most 
effective and most lethal 24 hour interval schedule for 
a patient can be separated by only a few hours, with 
larger variability of treatment efficacy and toxicity 
being seen among women (Bernard et al., 2010). Still, 
the inclusion of a time-dependent aspect of drug 
administration should be considered since it can allow 
for more effective and less harmful treatments for 
cancer in some individuals. 
Conclusion 
Evidence from epidemiologic studies, cellular studies, 
rodent studies, and clinical trials all indicate that the 
genesis and proliferation of cancer can result from 
circadian abnormalities and be altered by circadian-
based treatments. Genetically or environmentally 
disrupted circadian processes seem to counteract the 
naturally inhibitive properties of circadian gene 
expression and melatonin on oncogenesis present in 
both rodents  
and humans with properly aligned rhythms. This 
connection is expressed such that circadian disruption 
appears to both induce tumorigenesis and cause poorer 
outcomes from cancer, whereas maintained rhythms 
seem to inhibit oncogenesis and increase survival rates. 
Because circadian rhythms span across many levels of 
complexity within an organism, they must be 
understood on multiple levels from circadian genes to 
behavior. Cancer treatment or prevention may be 
modified at one or more of these levels, and it should 
be understood that circadian variables are both present 
within the patient and are able to be manipulated by the 
environment when trying to determine an effective 
treatment plan. 
Currently, the clinical trials using chronotherapy that 
have been conducted to date have produced some 
promising and some seemingly inconsistent results. 
However, when examining the results of clinical trials, 
baseline gender, cancer, and circadian differences must 
be taken into account which may resolve perceived 
inconsistencies. It could be that chronomodulated 
delivery of drugs is only preferable in hormonally 
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regulated cancers, useful in males but not females, or 
only advantageous when the patient's circadian 
rhythms are intact. Although many unknowns remain 
in circadian rhythms and cancer interaction, it seems 
clear that there is a circadian component to both the 
induction and progression of several types of cancer, 
and this compilation of information suggests that 
cancer prevention and treatment should include 
circadian aspects in order to be maximally effective. 
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